Menu Search
Equities

Zydus Lifesciences Ltd

ZYDUSLIFE:NSI

Zydus Lifesciences Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)949.05
  • Today's Change7.75 / 0.82%
  • Shares traded295.55k
  • 1 Year change+47.83%
  • Beta0.4057
Data delayed at least 15 minutes, as of Nov 22 2024 10:23 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy3
Outperform8
Hold9
Sell4
Strong Sell3

Share price forecast in INR

The 27 analysts offering 12 month price targets for Zydus Lifesciences Ltd have a median target of 1,090.00, with a high estimate of 1,380.00 and a low estimate of 490.00. The median estimate represents a 15.80% increase from the last price of 941.30.
High46.6%1,380.00
Med15.8%1,090.00
Low-47.9%490.00

Dividends in INR

In 2024, Zydus Lifesciences Ltd reported a dividend of 3.00 INR, which represents a 50.00% decrease from last year. The 21 analysts covering the company expect dividends of 6.50 INR for the upcoming fiscal year, an increase of 116.63%.
Div growth (TTM)-50.00%
More ▼

Earnings history & estimates in INR

On Nov 12, 2024, Zydus Lifesciences Ltd reported 2nd quarter 2025 earnings of 9.06 per share. This result was in line with the consensus of the 4 analysts following the company and exceeded last year's 2nd quarter results by 14.54%.
The next earnings announcement is expected on Feb 07, 2025.
Average growth rate+8.35%
Zydus Lifesciences Ltd reported annual 2024 earnings of 38.00 per share on May 17, 2024.
Average growth rate+37.14%
More ▼

Revenue history & estimates in INR

Cadila Healthcare Limited had 2nd quarter 2025 revenues of 52.37bn. This bettered the 51.85bn consensus of the 14 analysts covering the company. This was 1.90% above the prior year's 2nd quarter results.
Average growth rate+5.62%
Cadila Healthcare Limited had revenues for the full year 2024 of 195.47bn. This was 13.40% above the prior year's results.
Average growth rate+8.34%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.